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Abstract: Introduction: Testis cancer is a rare cancer that afflicts young men. although the incidence of testis cancer is
increasing, the mortality rate is decreasing. This study examines the mortality of testicular cancer and its re-
lationship with the human development index and its components in Iran during 2005-2015. Materials and
Methods: Data of patients with testis cancer were collected from the Office of National Cancer Registry in the
Ministry of Health and Medical Education (MOH&ME) during 2005-2015. An additional telephone survey was
conducted by trained interviewers to collect data, including survival status, demographic characteristics, age
of cancer diagnosis and other clinical profiles. Kaplan-Meier survival rates were calculated according to demo-
graphic characteristics, economic status, and residential area and socioeconomic status (SES). All the analyses
were done using STATA software, version 14 (StataCorp. 2015). Results: From 2005 to 2015, 5886 testicular
cancer cases were diagnosed among men in all age groups. Most patients (73.9%) were 15–49 years of age at
the time of diagnosis, 26.1% were 50 years of age or older. Seminoma was diagnosed among 46.78% of the pa-
tients and non-seminoma among 42.28%. Factors which had impact on survival rate were age (P=0.001), tumor
histology (P=0.02, hazard ratio=1.23[0.98-1.38]) and TNM stage (P=0.001, hazard ratio=1.2[0.92-1.28]). Patients
who got married at the time of diagnosis more likely presented at earlier stages and had better overall testis
cancer-specific survival than patients who were single, separated, widowed, or divorced (P=0.002, hazard ratio
1.27[1.09-1.49]). Testis cancer mortality rate was significantly higher in patients who did not graduate from high
school and significantly higher in patients who were tenants (P=0.057, hazard ratio =1.132[0.996-1.28]). Con-
clusion: Testis cancer mortality is decreasing in Iran. Age, TNM stage and histology, and marital and economic
status were factors influencing mortality rate.
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1. Introduction
Although testis cancer is a rare disease (1) but it is the most
common solid malignancy among young men (2). For un-
known reasons, the incidence of testis cancer continues to
increase and it has been doubled in North America and most
European countries during the last 20 years (3, 4). However,
the cancer mortality rate continues to decrease which could
be due to sophisticated diagnostic imaging modalities, to-
gether with improvements in surgical techniques, and devel-
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opment of multidrug chemotherapeutic agents (3). The cur-
rent five-year survival rate for all stages of testis cancer ex-
ceeds 80% and approaches 100% for patients with low stage
disease (5). The tumor histology, tumor size, the extent to
which cancer has spread, patient’s age and socioeconomic
status (SES) have been discussed as prognostic factors (6).
Knowing the data about the testicular cancer incidence and
mortality could be useful for health programming and re-
search activities in the field of testis cancer. However, limited
information is available about the incidence and mortality of
testis cancer in Iran. This study examines the mortality of
testicular cancer and its relationship with the human devel-
opment index and its components in Iran during 2005-2015.
2. Materials and Methods
This is a retrospective study in which data of patients with
testis cancer were collected from the Office of National Can-
cer Registry in the Ministry of Health and Medical Education
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(MOHME) during 2005-2015. An additional telephone sur-
vey was conducted by trained interviewers to collect data, in-
cluding survival status, demographic characteristics, age of
cancer diagnosis and other clinical profiles. Patients were
questioned using a structured interview schedule about sev-
eral variables that influence SES such as educational attain-
ment, income, housing, and employment variables. Accord-
ing to the study protocol, three telephone calls within two
consecutive weeks were considered as a sufficient attempt to
collect data. Using Cox regression model and survival anal-
ysis, Kaplan-Meier survival rates were calculated according
to demographic characteristics, economic status, residential
area, and SES. All the analyses were done using STATA soft-
ware, version 14 (StataCorp. 2015. Stata Statistical Software:
Release 14. College Station, TX: StataCorp LP), and P<0.05
was considered statistically significant.
3. Results
From 2005 to 2015, 5886 testicular cancer cases were diag-
nosed among men in all age groups. In these 10 years, there
was an average of 840 cases diagnosed per year. Most pa-
tients (73.9%) were 15–49 years of age at the time of diag-
nosis, 26.1% were 50 years of age or older. Seminoma was
diagnosed among 46.78% of the patients and non-seminoma
among 42.28%. Other histological types and unspecified can-
cers were diagnosed in 10.94% of patients. Testicular cancer
mortality declined from 0.78/100,000 to 0.51/100,000 From
2005-2015.
Figure 1 presents the five-year relative survival for testicular
cancer in Iran from 2005 to 2015. The total five-year relative
survival for testicular cancer was 70.2% during 2005–2015.
Factors affecting survival rate were age (P=0.001), tumor his-
tology (P=0.02, hazard ratio=1.23[0.98-1.38]) and TNM stage
(P=0.001, hazard ratio=1.2[0.92-1.28]). Increasing age was as-
sociated with reduced relative survival. Slightly higher sur-
vival was observed in the seminoma group, (93.98%, 95% CI:
80.9 to 100), than in the non-seminoma group (87.94%, 95%
CI: 77.3 to 94.2). By TNM summary stage, the five-year rela-
tive survival was 97.23% for localized tumor stage I, 94.36%
for stage II, 64.77% for stage III, and 54.67% for unknown
stage.
Patients who were married at the time of diagnosis more
likely presented at earlier stages and had better overall testis
cancer-specific survival than patients who were single, sepa-
rated, widowed, or divorced (P=0.002, hazard ratio 1.27[1.09-
1.49])(Figure 2). Married men had both a decreased risk of
all-cause mortality (hazard ratio: 0.58; 95% CI: 0.53–0.63) and
of testis cancer specific mortality (hazard ratio: 0.60, 95% CI:
0.53–0.69), even after controlling for age at diagnosis, year of
diagnosis, disease stage, and tumor type. In this study, family
history was not significantly associated with the risk of can-
cer mortality (P= 0.595, figure 3). In terms of SES, the mor-
tality of testis cancer was significantly higher in patients who
did not graduate from high school and patients who are ten-
ants (P=0.026, figure 4). The patients’ occupation was not sig-
nificantly associated with cancer mortality rate (P=0.49).
4. Discussion
In this study, we analyzed the survival rate of testis cancer in
Iran from 2005 to 2015. The introduction of cisplatin-based
therapies in the late 1970s led to a decrease in the mortality
rate of testis cancer, with survival rates reaching 95% (7). It
has been stated that the decline of testicular cancer mortal-
ity in Eastern European countries started in the 1980s, but at
a rate slower than that recorded in Western Europe (8). In this
study, overall five-year survival rate increased slightly (10.1%)
from 2005–2010 to 2010–2015 (from 65.2% to 75.2%). Similar
mortality changes were reported in other Western countries
(8). The reason behind that is the better diagnostic tools and
the development of new chemotherapeutic agent. Moreover,
the shift in attitudes to men’s health contributes to early di-
agnosis and better outcomes.
The highest five-year survival rate was seen in Northern Eu-
rope (92.8%), followed by 91.8% for Central Europe, 89.1%
for Southern Europe, and 80.1% for Eastern Europe (9). In
this study, the five-year survival rate was 70.2% in Iran. The
survival for patients with seminoma was always higher than
that for non-seminomas in Europe and in all the European
regions (9). In our study, a five-year survival was still lower
compared to other countries. Differences in five-year relative
survival between our study and other Northern European
countries was a cause of concern. Possible factors explain-
ing these differences could be: limited access to appropri-
ate therapies, delayed treatment, or lack of evidence-based
guidelines.
This study was able to represent the independent effect of age
on the prognosis of testicular cancer. In a study by Fossa et
al., the adverse impact of increasing age on testicular cancer-
specific mortality was noted. Reduced treatment intensity
combined with increased therapy-related toxicity is a plau-
sible explanation for increased testicular carcinoma-specific
mortality in patients older than 40 years (6). Hoffman et al.
showed that low sociodemographic status reduced the like-
lihood of being offered radiotherapy (10, 11). In their study,
men residing in countries with a higher education level were
more likely to receive adjuvant radiotherapy for stage I semi-
noma than men residing in countries with a lower education
level. This study showed that patients with low socioeco-
nomic status were more likely to succumb to death. Delayed
treatment or limited access to appropriate treatment might
explain the difference in the mortality rate in people with dif-
ferent socioeconomic status in this study.
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In our study, Marital status was an independent predictor of
improved overall survival in men with testis cancer. Abern
and colleagues showed that being married (P<0.001) and
Caucasian race (P< 0.001) independently predicted improved
testis cancer-specific survival, while increased age (P<0.001),
increased stage (P<0.001), and non-seminomatous germ cell
tumor (P<0.001) histology independently predicted testis
cancer-specific death (12). There are two reasons for our
findings. First, married men may be urged to seek medical
attention sooner once they have symptoms or a physical ab-
normality is detected. Second, married men are more likely
to seek evaluation for male factor infertility; therefore, testis
tumor is diagnosed in an early stage.
Sandrucci et al. and Blay et al. explained that patients with
rare cancers should be treated at centers from the beginning
of their clinical history with a multidisciplinary clinical deci-
sion on how to plan treatment which can largely determine
patient outcomes (13, 14). The quality of cancer registration
and the number of the missed cases in this study make our
study less reliable. Despite the limitations of this study, this
nationwide analysis highlights changes in testicular cancer
incidence, mortality, and survival, indicating an existing gap
for survival improvement
5. Conclusion
Testis cancer is a rare cancer that mostly afflicts the young
population. Although the incidence of testis cancer is in-
creasing in Iran, the mortality rate is decreasing. Age, TNM
stage and histology, and marital and economic status are fac-
tors which influence mortality rate. Family history of testis




6.2. Conflict of interest




All the authors have the same contribution.
References
1. Ross R, McCurtis J, Henderson B, Menck H, Mack T,
Martin S. Descriptive epidemiology of testicular and pro-
static cancer in Los Angeles. British journal of cancer.
1979;39(3):284-92.
2. Richie JP. Detection and treatment of testicular cancer.
CA: a cancer journal for clinicians. 1993;43(3):151-75.
3. Curreri SA, Fung C, Beard CJ, editors. Secondary malig-
nant neoplasms in testicular cancer survivors. Urologic
Oncology: Seminars and Original Investigations; 2015:
Elsevier.
4. Horner M, Ries L, Krapcho M. SEER Cancer Statistics
Review, 1975–2006. Bethesda, MD: National Cancer Insti-
tute 2009: h ttp. seer cancer gov/csr/1975_2006/, based
on November. 2008.
5. Hawksworth DJ, McLeod DG, Brassell SA, editors. Ad-
vances made in the treatment of testicular cancer in the
US Military: 1946 to the present. Urologic Oncology:
Seminars and Original Investigations; 2009: Elsevier.
6. Fosså SD, Cvancarova M, Chen L, Allan AL, Olden-
burg J, Peterson DR, et al. Adverse prognostic factors for
testicular cancer–specific survival: a population-based
study of 27,948 patients. Journal of Clinical Oncology.
2011;29(8):963-70.
7. Park JS, Kim J, Elghiaty A, Ham WS. Recent global
trends in testicular cancer incidence and mortality.
Medicine. 2018;97(37).
8. Levi F, La Vecchia C, Boyle P, Lucchini F, Negri E. West-
ern and eastern European trends in testicular cancer
mortality. The Lancet. 2001;357(9271):1853-4.
9. Trama A, Foschi R, Larrañaga N, Sant M, Fuentes-
Raspall R, Serraino D, et al. Survival of male genital can-
cers (prostate, testis and penis) in Europe 1999–2007: Re-
sults from the EUROCARE-5 study. European Journal of
Cancer. 2015;51(15):2206-16.
10. Hoffman KE, Chen M-H, Punglia RS, Beard CJ,
D’Amico AV. Influence of year of diagnosis, patient age,
and sociodemographic status on recommending adju-
vant radiation treatment for stage I testicular seminoma.
Journal of clinical oncology. 2008;26(24):3937.
11. Woods L, Rachet B, Coleman M. Origins of socio-
economic inequalities in cancer survival: a review. An-
nals of oncology. 2006;17(1):5-19.
12. Abern MR, Dude AM, Coogan CL, editors. Marital
status independently predicts testis cancer survival—an
analysis of the SEER database. Urologic Oncology: Semi-
nars and Original Investigations; 2012: Elsevier.
13. Sandrucci S, Gatta G. Rare cancers: A network
for better care. European Journal of Surgical Oncology.
2019;45(1):1-2.
14. Blay J-Y, Soibinet P, Penel N, Bompas E, Duffaud F,
Stoeckle E, et al. Improved survival using specialized mul-
tidisciplinary board in sarcoma patients. Annals of On-
cology. 2017;28(11):2852-9.
This open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).
Downloaded from: www.jmp.iums.ac.ir
M R. Abedi et al. 4
Figure 1: Kaplan-Meier overall survival analysis of testis cancer. Overall 5-year survival rate: 70.2% (CI95% 67.4-73).
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Figure 2: Kaplan-Meier survival analysis of testis cancer according to marital status.
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Figure 3: Kaplan-Meier survival analysis of testis cancer according to family history of cancer.
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Figure 4: Kaplan-Meier survival analysis of testis cancer according to marital and economic status.
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